Posts Tagged ‘Yondelis’
Today’s post was written by Bert E. Thomas IV, PhD, MBA, CEO of the Sarcoma Foundation of America. There was a long period of time where there seemed to be little to no progress in finding ways to battle the forgotten cancer known as sarcoma. This period of time lasted for decades, though it probably felt more like centuries to the patients and families that were desperately looking for treatment options that never seemed to come. And while sarcoma still takes too many of our loved ones from us, progress in our fight against this terrible disease is finally being… Read More »
-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment of advanced liposarcoma and leiomyosarcoma, two subtypes of soft tissue sarcoma. Yondelis has received approval for the use in the treatment of patients with unresectable or metastatic liposarcoma and leiomyosarcoma who have previously received an anthracycline chemotherapy. “The Sarcoma Foundation of America is thrilled with the FDA’s decision to approve… Read More »